REMINDER: Our user survey closes on Friday, please submit your responses here.
As I mentioned in my previous post TRUSPINE expected valuation a bit disappointing to be honest , hopefully will make a better debut than expected, rest of the update good/expected from what I have read
So prim have 1,666,667 shares in truspine at a cost of £500,000 so cost per share of 30p per share
If the target market cap is £31.5 million and 92.5 million shares that works out as 34p per share
Hopefully the IPO will start strong
I think you'll find Spreadex just take a position to mirror their clients exposure, otherwise they would get crucified if the share price rocketed, dont forget , currently 100% of positions are currently long on GDR so potentially a big exposure. I have a small position in GDR too with spreadex and have traded with them for 15+ years
ST I see what you mean, samolly and philjpo posting the same recollection of an investor in a nickel company, rumbled I think, there for all to see , a de-ramp crew in operation says it all, hopefully genuine investors will now treat these I'd,s with caution, they are not genuine , classic slip up
Sam , for someone who supposedly holds, you really like talking your investment down , being realistic is one thing but your outright negative so doesn't make much sense to me if you are genuinely a holder unless you want to buy more at a cheaper price that is
Once approvals start rolling in the mood on the board will be much more positive , an improved covid19 offering would surely improve the outlook for sales too , a lot to look forward too in the near future from my perspective . The Rns shows confidence in the product and potential sales outcome so happy to wait for that to come to fruition
full RNS here
Genedrive PLC New Genedrive(R) 96 Exporter software
10/07/2020 7:01am
RNS Non-Regulatory
TIDMGDR
Genedrive PLC
10 July 2020
genedrive plc
("genedrive" or the "Company")
New Genedrive(R) 96 Exporter software
Easy-to-use analysis tool to support high-throughput Coronavirus PCR testing
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that it has developed and now CE marked Genedrive(R) 96 Exporter, a new IVD software module for automated results interpretation of the Genedrive(R) 96 SARS-CoV-2 Kit. genedrive is one of only a handful of companies offering a full laboratory workflow solution for the analysis of extracted COVID-19 RNA Polymerase Chain Reaction ("PCR") samples, including the test reagents, instrument protocols, and automated analysis software.
The Genedrive(R) 96 Exporter has been developed to provide further workflow and usability advantages to the Genedrive(R) 96 SARS-CoV-2 kit. The software module extracts the raw fluorescence run data from third party high throughput real time PCR platforms, analyses the PCR melt-curve data generated using the Genedrive(R) 96 SARS-CoV-2 Kit. It displays the interpreted data as 'Positive' or 'Negative' in a graphical user interface and as an exportable report. The interpreted data is then available for further inspection on an individual sample, sample group, or entire 96 well plate basis by the user.
The Genedrive(R) 96 SARS-CoV-2 Kit is a novel CE Marked PCR assay designed to detect active infection in COVID-19 patients. genedrive's one-step PCR bead format eliminates the need for the time consuming and error-prone reagent preparation required in other open-platform test kits. The proprietary format streamlines laboratory workflow, allowing more tests to be performed in a day. During CE-IVD evaluations, the Genedrive(R) 96 SARS-CoV-2 Kit achieved 100% sensitivity and 98% specificity in randomised clinical specimens.
David Budd, Chief Executive Officer of genedrive plc, said: "The new Genedrive(R) 96 Exporter software provides a significant improvement to the native software found on third party PCR platforms, allowing for a more seamless workflow for melt curve PCR analysis in COVID-19 PCR testing when using our assay. The tool was developed by repurposing the clinically validated software algorithms we use in our point-of-care Genedrive(R) instrument software, underscoring the versatility and value in our core technology platform and providing additional differentiation to genedrive's offerings in the COVID-19 testing market."
genedrive plc +44 (0)161 989 0245
David Budd: CEO / Matthew Fowler:
CFO
Peel Hunt LLP (Nominated Adviser
and Joint Broker) +44 (0)20 7418 8900
James Steel / Oliver Jackson
finnCap (Joint Broker)